Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-κB pathway in lung cancer cells

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1289-1296

  Ke, Shi Zhong ^a   Ni, Xiao Yan ^a   Zhang, Yue Hua ^a   Wang, Yi Nan ^a   Wu, Bin ^b   Gao, Feng Guang ^a  

^a XIAMEN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ABCG2; Ataxia telangietisa mutanted; Lung cancer; MRP2; NF B

Indexed keywords

ATM PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN BCL 2;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84874588590     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1805     Document Type: Article

References (43)

1. Tan XL, Moyer AM, Fridley BL, et al: Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 17:5801-5811, 2011.
2. Shinoda C, Maruyama M, Fujishita T, et al: Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway. Int J Cancer 117:21-31, 2005.
3. Spiro SG, Tanner NT, Silvestri GA, et al: Lung cancer: progress in diagnosis, staging and therapy. Respirology 15:44-50, 2010.
4. Yamazaki R, Nishiyama Y, Furuta T, et al: Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther 10:1252-1263, 2011.
5. Kim DH, Sriharsha L, Xu W, et al: Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15:4750-4758, 2009.
6. Doyle LA and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358, 2003.
7. Robey RW, Medina-Pérez WY, Nishiyama K, et al: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145-152, 2001.
8. Candeil L, Gourdier I, Peyron D, et al: ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 109:848-854, 2004.
9. Diestra JE, Scheffer GL, Catala I, et al: Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198:213-219, 2002.
10. Turne JG, Gump JL, Zhang C, et al: ABCG2 expression, function and promoter methylation in human multiple myeloma. Blood 108:3881-3889, 2006.
11. Yamasaki M, Makino T, Masuzawa T, et al: Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104:707-713, 2011.
12. Chen ZS and Tiwari AK: Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 278:3226-3245, 2011.
13. Spanswick VJ, Lowe HL, Newton C, et al: Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer 12:436, 2012.
14. Gaudio E, Spizzo R, Paduano F, et al: Tcl1 interacts with ATM and enhances NF-. B activation in hematologic malignancies. Blood 119:180-187, 2012.
15. Svirnovski AI, Serhiyenka TF, Kustanovich AM, Khlebko PV, Fedosenko VV, Taras IB and Bakun AV: DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells. Exp Oncol 32:258-262, 2010.
16. Bae JB, Mukhopadhyay SS, Liu L, et al: Snm1B/Apollo mediates replication fork collapse and S Phase checkpoint activation in response to DNA interstrand cross-links. Oncogene 27:5045-5056, 2008.
17. Bakkenist CJ and Kastan MB: DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506, 2003.
18. Karin M and Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759, 2005.
19. Lin Y, Bai L, Chen W and Xu S: The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 14:45-55, 2010.
20. Campbell KJ, O'Shea JM and Perkins ND: Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors. BMC Cancer 6:101, 2006.
21. Melisi D and Chiao PJ: NF-kappa B as a target for cancer therapy. Expert Opin Ther Targets 11:133-144, 2007.
22. Konstantinopoulos PA, Fountzilas E, Pillay K, et al: Carboplatininduced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 1:59, 2008.
23. Wu ZH, Shi Y, Tibbetts RS and Miyamoto S: Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 311:1141-1146, 2006.
24. Hu SX, Sui HX, Jin HJ, et al: Lipopolysaccharide and dose of nicotine determine the effects of nicotine on murine bone marrow-derived dendritic cells. Mol Med Rep 5:1005-1010, 2012.
25. Zhang L, Yu H, Zhao X Lin X, Tan C, Cao G and Wang Z: Neuroprotective effects of salidroside against beta-amyloidinduced oxidative stress in SH-SY5Y human neuroblastoma cells. Neurochem Int 57:547-555, 2010.
26. Buhrmann C, Mobasheri A, Busch F, Aldinger C, Stahlmann R, Montaseri A and Shakibaei M: Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 286:28556-28566, 2011.
27. Dioum EM, Osborne JK, Goetsch, S Russell J, Schneider JW and Cobb MH: A small molecule differentiation inducer increases insulin production by pancreatic β cells. Proc Natl Acad Sci USA 108:20713-20718, 2011.
28. Jin HJ, Li HT, Sui HX, Xue MQ, Wang YN, Wang JX and Gao FG: Nicotine stimulated bone marrow-derived dendritic cells could augment HBV specific CTL priming by activating PI3K-Akt pathway. Immunol Lett 146:40-49, 2012.
29. Heo JI, Oh SJ, Kho, et al: ATM mediates interdependent activation of p53 and ERK through formation of a ternary complex with p-p53 and p-ERK in response to DNA damage. Mol Biol Rep 39:8007-8014, 2012.
30. Ai L, Skehan RR, Saydi J, Lin T and Brown KD: Ataxiatelangiectasia, mutated (ATM)/nuclear factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem 287:18330-18341, 2012.
31. Togashi H, Sasaki M, Frohman E, et al: Neuronal (type I) nitric oxide synthase regulates nuclear factor κB activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci USA 94:2676-2680, 1997.
32. Tenopoulou M, Kurz T, Doulias PT, Galaris D and Brunk UT: Does the calcein-AM method assay the total cellular 'labile iron pool' or only a fraction of it? Biochem J 403:261-266, 2007.
33. Zolner AE, Abdou I, Ye R, et al: Phosphorylation of polynucleotide kinase/phosphatase by DNA-dependent protein kinase and ataxia-telangiectasia mutated regulates its association with sites of DNA damage. Nucleic Acids Res 39:9224-9237, 2011.
34. Alexande A, Cai SL, Kim J, et al: ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 107:4153-4158, 2010.
35. Korita PV, Wakai T, Shirai Y, et al: Multidrug resistance associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 23:965-972, 2010.
36. Yasui K, Mihara S, Zhao C, et al: Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64:1403-1410, 2004.
37. Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, Miele L and Beck WT: Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci USA 108:20778-20783, 2011.
38. Bram EE, Stark M, Raz S and Assaraf YG: Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 11:1359-1370, 2009.
39. Yang Y, Xia F, Hermance N, et al: A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol 31:2774-2786, 2011.
40. Miyamoto S: Nuclear initiated NF-κB signaling: NEMO and ATM take center stage. Cell Res 21:116-130, 2011.
41. Wu ZH and Miyamoto S: Induction of a pro-apoptotic ATM-NF-κB pathway and its repression by ATR in response to replication stress. EMBO J 27:1963-1973, 2008.
42. Ling J, Kang Y, Zhao R, et al: KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21:105-120, 2012.
43. Li F and Sethi G: Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805:167-180, 2010.